This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1988;6(5):589-95.

doi: 10.3109/07357908809082124.

Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations

V C Jordan¹

Affiliations

PMID: 3063338
DOI: 10.3109/07357908809082124

Review

Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations

V C Jordan. Cancer Invest. 1988.

. 1988;6(5):589-95.

doi: 10.3109/07357908809082124.

Author

V C Jordan¹

Affiliation

¹ University of Wisconsin Clinical Cancer Center, Madison, Wisconsin.

PMID: 3063338
DOI: 10.3109/07357908809082124

No abstract available

PubMed Disclaimer

Similar articles

Chemosuppression of breast cancer with long-term tamoxifen therapy.
Jordan VC. Jordan VC. Prev Med. 1991 Jan;20(1):3-14. doi: 10.1016/0091-7435(91)90002-l. Prev Med. 1991. PMID: 2008427 Review.
Long-term adjuvant tamoxifen therapy for breast cancer: the prelude to prevention.
Jordan VC. Jordan VC. Cancer Treat Rev. 1990 Mar;17(1):15-36. doi: 10.1016/0305-7372(90)90074-p. Cancer Treat Rev. 1990. PMID: 2224868 Review. No abstract available.
Chemoprevention for breast cancer: are we ready?
Kiang DT. Kiang DT. J Natl Cancer Inst. 1991 Apr 3;83(7):462-3. doi: 10.1093/jnci/83.7.464. J Natl Cancer Inst. 1991. PMID: 2005624 No abstract available.
Tamoxifen for the prevention of breast cancer: yes.
Vogel VG, Saenz M. Vogel VG, et al. Important Adv Oncol. 1995:187-200. Important Adv Oncol. 1995. PMID: 7672805 Review. No abstract available.
Antiestrogens as chemopreventive agents in breast cancer: promise and issues in evaluation.
Love RR. Love RR. Prev Med. 1989 Sep;18(5):661-71. doi: 10.1016/0091-7435(89)90037-6. Prev Med. 1989. PMID: 2694160 Review.

See all similar articles

Cited by

SERMs for the treatment and prevention of breast cancer.
Swaby RF, Sharma CG, Jordan VC. Swaby RF, et al. Rev Endocr Metab Disord. 2007 Sep;8(3):229-39. doi: 10.1007/s11154-007-9034-4. Rev Endocr Metab Disord. 2007. PMID: 17440819 Review.
Beyond raloxifene for the prevention of osteoporosis and breast cancer.
Jordan VC. Jordan VC. Br J Pharmacol. 2007 Jan;150(1):3-4. doi: 10.1038/sj.bjp.0706962. Epub 2006 Nov 20. Br J Pharmacol. 2007. PMID: 17115068 Free PMC article.
The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.
Fan P, Maximov PY, Curpan RF, Abderrahman B, Jordan VC. Fan P, et al. Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3(0 3):245-63. doi: 10.1016/j.mce.2015.06.004. Epub 2015 Jun 5. Mol Cell Endocrinol. 2015. PMID: 26052034 Free PMC article. Review.
Long-term adjuvant tamoxifen therapy for breast cancer.
Jordan VC. Jordan VC. Breast Cancer Res Treat. 1990 May;15(3):125-36. doi: 10.1007/BF01806350. Breast Cancer Res Treat. 1990. PMID: 2196941 Review.
Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.
Ko SS, Jordan VC. Ko SS, et al. Expert Opin Pharmacother. 2011 Mar;12(4):657-74. doi: 10.1517/14656566.2011.557360. Epub 2011 Feb 7. Expert Opin Pharmacother. 2011. Retraction in: Expert Opin Pharmacother. 2012 May;13(7):1081. doi: 10.1517/14656566.2012.677336. PMID: 21294695 Free PMC article. Retracted. Review.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

P01-CA20432/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Atypon
Medical
- MedlinePlus Health Information